IT·SCIENCE

Daedeok biotech firms ink MOU with Johns Hopkins to expand US market push

by
Koo Bon-hyuk
Published : Nov. 16, 2026 - 16:19:09
    • Copy Completed!

View Korean Original

- Signs MOU with Johns Hopkins Global Biomedical Innovation Center

- Agreement to support joint research, technology validation and US market entry

Participants pose for a photo after signing an MOU on Monday. From left: Im Moon-taek, head of the Daedeok Research and Development Special Zone under the Korea Research Institute of Science and Technology Promotion; and Kim Deok-ho, professor of biomedical engineering at Johns Hopkins University and director of JHBIC.
Participants pose for a photo after signing an MOU on Monday. From left: Im Moon-taek, head of the Daedeok Research and Development Special Zone under the Korea Research Institute of Science and Technology Promotion; and Kim Deok-ho, professor of biomedical engineering at Johns Hopkins University and director of JHBIC.

Biotech companies in the Daedeok Research and Development Special Zone are joining forces with Johns Hopkins University to break into the US market.

The Daedeok R&D Special Zone office of the Korea Research Institute of Science and Technology Promotion signed a memorandum of understanding Monday with the Johns Hopkins Global Biomedical Innovation Center (JHBIC) at the Daedeok Connect Lounge inside the Daejeon Science Complex, formalizing cooperation on global technology commercialization in advanced biotech.

The agreement is designed to elevate existing technology exchanges between Daedeok-based research institutions and companies and Johns Hopkins researchers into an official cooperation framework. It focuses particularly on supporting South Korean biotech firms in pursuing international joint research, technology validation and entry into the US market.

The two sides will work to identify collaboration opportunities between Daedeok institutions and Johns Hopkins researchers, and will pursue joint research, technology transfer and commercialization initiatives.

They also plan to hold regular expert exchanges and technology cooperation seminars and forums, and to share information on South Korean and US biotech policy and regulation to help Daedeok companies navigate the US market.

Following the signing ceremony, the two organizations co-hosted a "Global Biotech Partnership Showcase." The event brought together five advanced biotech companies from the Daedeok Special Zone and five overseas experts, including researchers from Johns Hopkins.

Participating companies presented their core technologies and discussed prospects for international joint research, technology cooperation and global commercialization with the overseas experts.

The Daedeok Special Zone office said it will use the collaboration leads identified at the event to facilitate follow-up work with Johns Hopkins researchers, with plans to develop them into concrete international joint research projects, global proof-of-concept initiatives and commercialization programs.

Johns Hopkins, the first research university in the United States, operates an integrated biomedical research system linking its medical school and hospital. Its strengths lie in a research infrastructure and global network spanning basic research, clinical application and technology commercialization.

According to the Daedeok Special Zone office, Johns Hopkins secured about $3.6 billion in US federal research funding in 2024, underscoring its standing as a world-class research institution.

"A strong cooperative foundation that allows advanced biotech companies to tap into overseas expertise and research capabilities is essential for entering global markets," said Im Moon-taek, head of the Daedeok Special Zone office. "We will expand our cooperation network with leading global innovation institutions to help Daedeok biotech companies build competitiveness in overseas markets."


nbgkoo@heraldcorp.com
This content was produced with the assistance of AI translation services.

MOST READ